Looking at Graybug Vision (NASDAQ:GRAY) and Perrigo (NYSE:PRGO)

Graybug Vision ( NASDAQ:GRAY – Get Your Free Report ) and Perrigo ( NYSE:PRGO – Get Your Free Report ) are both medical companies, but which is the superior stock? We’ll compare the two companies based on the strength of profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Risk and volatility

Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Rating and Earnings

This table compares Graybug Vision and Perrigo’s top-line revenue, earnings per share (EPS) and valuation.

Perrigo has higher revenue and earnings than Graybug Vision. Perrigo is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

return

This table compares Graybug Vision and Perrigo’s net margins, return on equity and return on assets.

Analyst recommendations

This is a summary of recent recommendations for Graybug Vision and Perrigo as provided by MarketBeat.

Perrigo has a consensus target price of $39.33, indicating a potential upside of 34.61%. Given Perrigo’s higher possible upside, analysts plainly believe Perrigo is more favorable than Graybug Vision.

Institutional and insider ownership

49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 7.9% of Graybug Vision shares are owned by insiders. Comparatively, 0.7% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, big money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Perrigo beats Graybug Vision in 8 of the 12 factors compared between the two stocks.

About Graybug Vision

(Get a free report)

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company’s lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in clinical trials of phase IIa. for the treatment of diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and has changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is headquartered in Redwood City, California.

About Perrigo

(Get a free report)

Perrigo Company plc provides over-the-counter health and wellness solutions to improve individual well-being in the United States, Europe and internationally. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Company develops, manufactures, markets and distributes consumer self-care products such as upper respiratory products, including antitussives, expectorants and sinus and allergy relief; Nutritional products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrhea and anti-heartburn; Pain and sleeping pills containing analgesics and fever reducers; and oral care products, which include toothbrushes, replacement toothbrush heads, dental floss, dental floss, whitening products and toothbrush covers. It also offers healthy lifestyle products such as smoking cessation, wellness and weight management products; skin care products consisting of dermatological care, scar management, lice treatment and other products for various skin conditions; women’s health products including feminine hygiene and contraceptives; vitamins, minerals and supplements; rare disease business; and other miscellaneous self-care products. The company sells its products under Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Brands Stops, XLS, Arterin, Davitamon, Apiserum, Abtei and Nicorette. They also offer contract manufacturing services. The company sells its products through drug retailers, supermarkets and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and food retailers; and parapharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Get news and reviews for Graybug Vision daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Graybug Vision and related companies with MarketBeat.com’s FREE daily email newsletter.